Why the study?
For patients with AMI complicated by CS undergoing primary PCI, the optimal timing of initiating IABP therapy remains unclear.
Does intra-aortic balloon pump (IABP) insertion before primary PCI improve short-term and long-term mortality compared to insertion after primary PCI in patients with acute myocardial infarction complicated by cardiogenic shock?
Does intra-aortic balloon pump (IABP) insertion before primary PCI improve short-term and long-term mortality compared to insertion after primary PCI in patients with acute myocardial infarction complicated by cardiogenic shock?
Answers are grounded in this paper and cite their sources.
The timing of IABP initiation (before vs after primary PCI) does not significantly impact short-term or long-term survival in patients with AMI complicated by cardiogenic shock.
BACKGROUND: For patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) undergoing primary percutaneous coronary intervention (PCI), the optimal timing of the initiation of intra-aortic balloon pump (IABP) therapy remains unclear. Therefore, we performed the first meta-analysis to compare the outcomes of IABP insertion before vs after primary PCI in this population. METHODS: Electronic databases of PubMed, EMBASE, and Cochrane Library were comprehensively searched from inception to April 1, 2019, to identify the eligible studies. The main outcomes were short-term (in-hospital or 30 days) and long-term (≥ 6 months) mortality. In addition, pooled analysis of risk-adjusted data were also performed to control for confounding factors. RESULTS: Seven observational studies and two sub-analysis of randomized controlled trials involving 1348 patients were included. Compared to patients inserted IABP after PCI, patients who received IABP therapy before primary PCI had similar risks of short-term (odds ratio [OR] 0.88, 95% CI 0.49 to 1.59) and long-term (OR 0.99, 95% CI 0.58 to 1.68) all-cause mortality. Moreover, a pooled analysis of risk-adjusted data also found similar effects of the two therapies on short-term (OR 0.65, 95% CI 0.34 to 1.25) and long-term (OR 0.68, 95% CI 0.17 to 2.72) mortality. Besides, no significant difference was found between the two groups with respect to reinfarction, repeat revascularization, stroke, renal failure, and major bleeding. CONCLUSIONS: The timing of the initiation of IABP therapy does not appear to impact short-term and long-term survival in patients with AMI complicated by CS undergoing primary PCI.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: